Company (Country/Symbol) Product Description Indication Action (Date) Alliance Pharmaceutical Corp. (ALLP) and Schering AG (Germany) Imagent Ultrasound contrast agent; aqueous dispersion of microbubbles containing mixture of perfluorochemical vapor and a physiological gas To improve ultrasound images of the walls of the heart Received approvable letter for the marketing of Imagent (8/21) Crescendo Pharmaceuticals Corp. and Alza Corp. (NYSE:AZA) Concerta Extended-release tablet formulation
State of the Industry Report | Thursday, January 3, 2002
Company Number of Shares Amount Raised Investors Agents Aastrom Biosciences Inc. 2.2 11 Aastrom sold 2.2M shares of 5.5onver- tible preferred stock to institutional invest- ors; each preferred share converts into 1 common share; it will convert automatically 2 years after purchase if Aastrom?s com- mon stock exceeds $10/share for 20 consec- utive trading days; Cowen & Co. acted as the placement agent in this all-or-none offering (11/97) Allelix Biopharmaceuticals Inc. (Canada
State of the Industry Report | Thursday, January 3, 2002
Company (Country/ Symbol) Company (Country/ Symbol) Type/ Product Area Terms/Details (Month) Abgenix Inc. (ABGX) Gliatech Inc. (GLIA) License and option agreement/use of Abgenix s XenoMouse technology to generate fully human monoclonal antibodies to the complement protein properdin for use in the fields of cardiovascular and inflammatory diseases Abgenix will receive a technology an access payment and could receive additional fees and milestones, plus royalties on product sales; Gliatech will
State of the Industry Report | Thursday, January 3, 2002
Staff Writer Merger among friends. A joining of equals. Synergy. Complementary technology. Pipeline expansion. Those were the words companies used in 2000 when asked about their mergers and acquisitions. In 2000, the biotechnology industry saw more than $14 billion worth of mergers and acquisitions, and more than 108 deals were completed. Among the biggest was the merger of Life Technologies Inc., of Rockville, Md., and Dexter Corp., of Windsor Locks, Conn. with Invitrogen Corp., of San
By Matthew Willett | State of the Industry Report | Thursday, January 3, 2002
Company Product Marketer Indication (U.S. Approval Date) Abbott Laboratories Inc. HIVAG-1 monoclonal antibody Abbott Laboratories Inc. Diagnostic for use in blood banks and plasma centers, and for prognostic use in HIV patients (4/96) Abbott Laboratories Inc. Norvir Abbott Laboratories Inc. Treatment of advanced AIDS (for use alone or in combination with nucleoside analogues); also treatment of earlier-stage AIDS (3/96) Activated Cell Therapy Inc. (now Dendreon Corp.) Devices used for
State of the Industry Report | Thursday, January 3, 2002
By Randall Osborne West Coast Editor It's all about money. Much is made in the popular press about advances made in biotechnology toward curing the health scourges of the world, such as AIDS and cancer, as well as finding fixes for rare, deadly genetic diseases caused by enzyme and hormone deficiencies. Such cures, the industry vows, are on the way. Once upon a time, the occasional article would take on ethics. Not ethics related to medical privacy and insurance, which has become well-trod
State of the Industry Report | Thursday, January 3, 2002
Company (Country/Symbol) Product Description Indication Action (Date) Alliance Pharmaceutical Corp. (ALLP) and Schering AG (Germany) Imagent Ultrasound contrast agent; aqueous dispersion of microbubbles containing mixture of perfluorochemical vapor and a physiological gas To improve ultrasound images of the walls of the heart Received approvable letter for the marketing of Imagent (8/21) Crescendo Pharmaceuticals Corp. and Alza Corp. (NYSE:AZA) Concerta Extended-release tablet formulation